Arga Setyo Adji

Dr. Arga Setyo Adji

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2022 in Open Access Macedonian Journal of Medical Sciences
Verified
Journal Article
Open access
PDF file
AAArga Setyo Adji
Arga Setyo Adji
NANabila Atika
Nabila Atika
YKYemima Billyana Kusbijantoro
Yemima Billyana Kusbijantoro
ABAtiyatum Billah
Atiyatum Billah
APAstrid Putri
Astrid Putri
FHFitri Handajani
Fitri Handajani
BACKGROUND: Bacterial gastroenteritis is a disease in the tropics in the form of inflammation of the stomach and intestines due to several bacteria, such as Salmonella, Campylobacter, Shigella, Escherichia coli, Vibrio, Yersinia, and Listeria with symptoms of diarrhea without or with vomiting and frequent fever. Gastroenteritis is a global disease with the highest prevalence in the agricultural community, especially farmers and fishermen. AIM: This research is to determine the potential of leaf and seed extract Moringa oleifera as an alternative therapy for bacterial gastroenteritis. METHODS: A literature review approach derived from the analysis and synthesis of various related references is used. The author selects journals full text and books published in the last ten years maximum through several databases, namely PubMed, Google Scholar, ScienceDirect, and Cochrane with the keywords: diarrhea, gastroenteritis, antibacterial, antiulcer, anti-inflammation, and M. oleifera. RESULTS: Seed and leaf extract M. oleifera played a role in preventing some of the effects of the pathogenesis of diarrhea due to bacterial infection. Methanol, N-hexane, ethyl acetate, flavonoids, phenols, saponins, alkaloids, tannins, and steroids from seed and leaf extract M. oleifera have antibacterial effects. The content of quercetin has an anti-inflammatory effect. The content of tannins, flavonoids, and alkaloids has antidiarrheal activity. The content of ethanol and tannins has an antiulcer effect. This potential can help cure patients with bacterial gastroenteritis. CONCLUSION: Leaf and seed extract of M. oleifera has good antibacterial, anti-inflammatory, antiulcer, and antidiarrheal potential for the treatment of bacterial gastroenteritis.

14 November 2024 in The Egyptian Heart Journal
Verified
Journal Article
Open access
PDF file
AAArga Setyo Adji
Arga Setyo Adji
JWJordan Steven Widjaja
Jordan Steven Widjaja
BLBryan Gervais de Liyis
Bryan Gervais de Liyis
Background: Mineralocorticoid receptor antagonists (MRAs) have been shown to improve outcomes in various populations of heart failure (HF) patients. However, the impact of concomitant diseases, such as diabetes mellitus (DM), on these outcomes remains unclear. This meta-analysis aimed to evaluate the efficacy and safety of MRAs in heart failure patients with and without diabetes mellitus. Methods: A systematic search was conducted on PubMed, Scopus, and Google Scholar databases up to April 30, 2024. Data analysis was performed using a random-effects model to account for variability across studies, and statistical analysis was carried out using Review Manager 5.4. Efficacy and safety parameters were evaluated in accordance with the Preferred Reporting Items for Systematic Review and Meta-Analysis guidelines. Results: The meta-analysis included a total of 21,832 subjects from ten studies. The pooled results demonstrated that MRAs, compared to placebo, significantly reduced all-cause mortality in HF patients with and without DM (RR: 0.85; 95%CI 0.75–0.96; p = 0.009). A similar effect was observed in HF patients without DM (RR: 0.83; 95%CI 0.71–0.97; p = 0.02), while no significant effect was detected in the DM subgroup (RR: 0.87; 95%CI 0.69–1.11; p = 0.27). Both treatments had comparable effects on cardiovascular mortality in HF patients with and without DM (RR: 0.88; 95%CI 0.82–0.94; p = 0.0002), in HF patients with DM (RR: 0.90; 95%CI 0.81–1.01; p = 0.08), and in the non-DM subgroup (RR: 0.86; 95%CI 0.79–0.94; p = 0.0009). MRAs significantly reduced the risk of cardiovascular mortality in HF patients with and without DM (RR: 0.82; 95%CI 0.72–0.94; p = 0.005) and in HF patients with DM (RR: 0.79; 95%CI 0.63–0.98; p = 0.03), but no significant effect was observed in the non-DM subgroup (RR: 0.85; 95%CI 0.69–1.05; p = 0.13). Furthermore, compared to placebo, MRAs were associated with an increased risk of hyperkalemia (> 5.5 mEq/L) in HF patients with and without DM (RR: 1.63; 95%CI 1.18–2.24; p = 0.003), particularly in HF patients with DM (RR: 1.44; 95%CI 0.97–2.13; p = 0.07) and in the non-DM subgroup (RR: 1.87; 95%CI 1.34–2.61; p = 0.0002). Conclusion: MRAs are effective in reducing all-cause mortality, cardiovascular death, and cardiovascular mortality in heart failure patients. However, the use of MRAs is associated with an increased risk of hyperkalemia, necessitating careful monitoring, particularly in patients with diabetes mellitus.

31 December 2024 in Osong Public Health and Research Perspectives
Verified
Journal Article
Open access
BRBetty Roosihermiatie
Betty Roosihermiatie
GPGurendro Putro
Gurendro Putro
AAArga Setyo Adji
Arga Setyo Adji
WYWindy Tri Yuana
Windy Tri Yuana
SSSelma Arsit Selto Siahaan
Selma Arsit Selto Siahaan
RRRustika Rustika
Rustika Rustika
Objectives: Malaria remains a serious public health challenge in tropical and subtropical regions, including Indonesia. Children under 5 years old face particular risk of contracting malaria due to low immunity. We examined potential factors associated with malaria infection among under-5 children in Papua Province, Indonesia.Methods: The study utilized secondary data from Indonesia Basic Health Research 2018. Multistage random sampling was employed, from the province level to census blocks (CBs). In Papua Province, interviews were conducted in 928 CBs. All 2,745 under-5 children were selected. The dependent variable was laboratory-confirmed malaria positivity; independent factors included residential area, socioeconomic characteristics, and behaviors such as sleeping under an insecticide net impregnated ≤3 years ago and the use of ventilation barriers. We also examined the conditions of the bedroom, kitchen, and living room according to the frequency of window-opening, proportion of ventilation area to the floor, and radiance.Results: Not sleeping under an insecticide net impregnated within the last 3 years (adjusted odds ratio [aOR], 0.518; 95% confidence interval [CI], 0.391–0.685; p<0.001); having a kitchen without windows (aOR, 0.491; 95% CI, 0.285–0.844; p=0.01); rarely opening the living room window (aOR, 2.804; 95% CI, 1.232–6.383; p=0.01), and having a windowless living room (aOR, 3.027; 95% CI, 1.369–6.696; p=0.01) displayed significant relationships with malaria infection among under-5 children.Conclusion: Not using an insecticide-treated net impregnated ≤3 years ago, along with opening the living room window daily and having a kitchen without windows, appear preventive of malaria infection among under-5 children.

10 January 2021 in Open Access Macedonian Journal of Medical Sciences
Verified
Journal Article
Open access
PDF file
ABAufa Baraja
Aufa Baraja
FSFadhilla Rachmawati Sunarto
Fadhilla Rachmawati Sunarto
AAArga Setyo Adji
Arga Setyo Adji
FHFitri Handajani
Fitri Handajani
FRFirman Suryadi Rahman
Firman Suryadi Rahman
BACKGROUND: Type 1 diabetes mellitus (T1DM) is a chronic disease in children which is usually caused by autoimmunity that damages pancreatic a and b cells which have functions as blood glucose regulators. Some studies stated that Renalase (RNLS) gene deletion will protect these b cells from autoimmune reactions and Endoplasmic Reticulum (ER) stress. RNLS deletion by genome editing Clustered Regular interspersed Short Palindromic Repeats-CRISPR-related (CRISPR/Cas9) is believed to have the potential to be a therapy for T1DM Patients. AIM: This research was conducted to know the potential of RNLS deletion using the CRISPR/Cas9 as an effective therapy and whether it has a permanent effect on T1DM patients. METHODS: The method applied in this research summarized articles by analyzing the titles and abstracts of various predetermined keywords. In this case, the author chose a full-text article published within the past 10 years by prioritizing searches in the last 5 years through PubMed, Google Scholar, Science Direct, Cochrane, American Diabetes Association, and official guidelines from IDAI. RESULTS: RNLS deletion using CRISPR/Cas9 in mice weakened the response of polyclonal -cell-reactive CD8+ T cells and disrupted the immune recognition to cells so that autoimmune killing did occur. In addition, such deletion prevents RNLS ER stress by increasing the threshold, triggering the unfolded protein response so that ER stress is difficult to occur. RNLS mutations in b cells also increase b cell survivability to oxidative stress. CONCLUSION: b cells RNLS deletion by genome editing CRISPR/Cas9 is effective in protecting b cells from autoimmune reactions and RE stress. However, further research is needed to determine the side effects and safety of its use.

14 June 2022 in Bali Medical Journal
Verified
Journal Article
Open access
PDF file
BSBambang Edi Suwito
Bambang Edi Suwito
AAArga Setyo Adji
Arga Setyo Adji
VWVira Aulia Kusuma Wardani
Vira Aulia Kusuma Wardani
JWJordan Steven Widjaja
Jordan Steven Widjaja
SASyalomitha Claudia Stefanie Angel
Syalomitha Claudia Stefanie Angel
FRFirman Rahman
Firman Rahman
Background: Targeting PCSK9 by maintaining hemodynamic shear stress stability has been shown in several studies to reduce LDL-C, arterial plaque formation, and PCSK9 expression in atherosclerotic cardiovascular disease. Genome editing with CRISPR-associated regularly interspersed short palindromic repeats (CRISPR/Cas9) have therapeutic potential for atherosclerotic cardiovascular disease. This study aims to evaluate the role of CRISPR/Cas9 in targeting PCSK9 as an effective therapeutic and long-term effect on atherosclerotic vascular disease. Methods: The method used in this study summarizes the article by looking for keywords that have been determined in the title and The authors used official guidelines from Science Direct, PubMed, the American College of Cardiology, Google Scholar, and PERKI to select full-text articles published within the last decade, prioritizing searches within the last five years. Results: CRISPR/Cas9 deletion of PCSK9 in mouse models reduces LDL-C, Plaque accumulation in the arteries, and PCSK9 expression. Furthermore, CRISPR/Cas9 deletion in PCSK9 saves the stability of Hemodyanimc shear stress to control the PCSK9 expression that causes Atherosclerotic cardiovascular disease. Conclusion: PCSK9 targeting by CRISPR/Cas9 deletion effectively reduces LDL-C, plaque buildup in the arteries, and PCSK9 expression. However, more research is needed to determine its side effects and safety.

9 August 2024 in The Egyptian Heart Journal
Verified
Journal Article
Open access
PDF file
AAArga Setyo Adji
Arga Setyo Adji
BLBryan Gervais de Liyis
Bryan Gervais de Liyis
Background: Atrial fibrillation (AF) poses a significant stroke risk in heart disease patients. This systematic review aims to evaluate the efficacy and safety of non-vitamin K oral antagonists (NOACs) versus vitamin K antagonists (VKAs) in AF patients with and without any valvular heart disease (VHD/N-VHD). Methods: A systematic search was conducted on PubMed, Scopus, and Google Scholar up to March 3, 2022. Efficacy and safety parameters were analyzed. Results: A total of 85,423 subjects from 10 studies were included in this meta-analysis. NOACs and VKAs showed similar effects on ischemic stroke in AF patients with VHD/N-VHD (RR 0.97; 95% CI 0.72–1.30; p = 0.83) and also on systemic embolic events (RR 1.02; 95% CI 0.83–1.25; p = 0.86). Similar effects were seen in VHD and N-VHD subgroups. Both treatments had similar effects on myocardial infarction in AF patients with VHD/N-VHD (RR 0.79; 95% CI 0.49–1.26; p = 0.32), VHD (RR 0.78; 95% CI 0.59–1.02; p = 0.07), and N-VHD subgroups (RR 0.82; 95% CI 0.30–2.21; p = 0.69). NOACs reduced the risk of intracranial bleeding in AF VHD/N-VHD (RR 0.64; 95% CI 0.54–0.77; p < 0.0001), VHD (RR 0.59; 95% CI 0.42–0.82; p = 0.002), and N-VHD subgroups (RR 0.70; 95% CI 0.57–0.85; p = 0.0003). Additionally, NOACs reduced the risk of gastrointestinal bleeding in AF VHD/N-VHD (RR 0.80; 95% CI 0.66–0.96; p = 0.02), specifically in the VHD subgroup (RR 0.69; 95% CI 0.54–0.89; p = 0.004). Moreover, NOACs were associated with a decreased risk for minor and non-fatal bleeding in AF patients with VHD/N-VHD (RR 0.86; 95% CI 0.75–0.99; p = 0.04). Conclusion: NOACs are effective and safe for ischemic stroke, systemic embolic events, myocardial infarction, intracranial bleeding, and gastrointestinal bleeding in AF patients with VHD/N-VHD.